Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma

Summary

This is a phase II study to determine the safety and efficacy of tislelizumab when given in combination with nab-paclitaxel as perioperative treatment in patients with muscle-invasive bladder cancer (MIBC) prior to cystectomy or complete TURBT. Patients will receive treatment with tislelizumab in combination with nab-paclitaxel every 3 weeks for 3 treatment cycles over 9 weeks followed by standard radical cystectomy or complete TURBT.

Timeline

Start

2020-07-11

Primary completion

2024-02

Completion

2024-07

Publications

• Shen C, Chai W, Han J, Zhang Z, Liu X, Yang S, Wang Y, Wang D, Wan F, Fan Z, Hu H. Identification and validation of a dysregulated TME-related gene signature for predicting prognosis, and immunological properties in bladder cancer. Front Immunol. 2023 Oct 27;14:1213947. doi: 10.3389/fimmu.2023.1213947. eCollection 2023.
• Shen C, Bi Y, Chai W, Zhang Z, Yang S, Liu Y, Wu Z, Peng F, Fan Z, Hu H. Construction and validation of a metabolism-associated gene signature for predicting the prognosis, immune landscape, and drug sensitivity in bladder cancer. BMC Med Genomics. 2023 Oct 26;16(1):264. doi: 10.1186/s12920-023-01678-6.

Drugs

Indications